The FDA has approved Ozempic (semaglutide) injection for the treatment of adults with type 2 diabetes.
Indications: Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.
Dosage and administration: Inject subcutaneously in the abdomen, thigh, or upper arm. Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly. Administer once weekly at any time of day, with or without meals. If a dose is missed, administer within 5 days of missed dose.
Adverse reactions: The most common adverse reactions (≥5% of patients) are nausea, vomiting, diarrhea, abdominal pain, and constipation.
Novo Nordisk receives FDA approval of OZEMPIC (semaglutide) injection for the treatment of adults with type 2 diabetes. [news release]. Novo Nordisk; Plainsboro, NJ; December 5, 2017. http://press.novonordisk-us.com/2017-12-5-Novo-Nordisk-Receives-FDA-Appr.... Accessed December 8, 2017.
Must Reads in Diabetes
Testosterone Therapy to Prevent T2D in Men, Diabetes Care; ePub 2019 Mar 18; Yassin, et al
Patterns of Diabetes Screening During Office Visits, J Am Board Fam Med; 2019 Mar-Apr; Shealy, et al
Muscular Strength and Incidence of Type 2 Diabetes, Mayo Clin Proc; ePub 2019 Mar 11; Wang, et al